Menu
Close
Stories & News
Resources
Stay Informed
x
Stay Informed
July 2, 2025
Breast cancer is the most common cancer among women globally –and a key focus of Pfizer’s leading oncology portfolio.
In today’s rapidly evolving treatment landscape, breast cancer therapy needs to be tailored to the individual patient. Our Oncology team’s deep understanding of breast cancer biology enables them to prioritize the advancement of innovative potential medicines for certain subtypes of breast cancer, while also working to overcome the biggest challenges in treatment.
In the latest Pfizer Pflash, Francesca DeMartino, Pfizer's Chief Investor Relations Officer, sat down with Johanna Bendell, Chief Development Officer for Pfizer Oncology, and Megan O’Meara, Head of Oncology Early Clinical Development, to discuss our breast cancer strategy, pipeline, and key milestones for promising potential new treatments. Our Pfizer Pflash webcasts, which feature discussions and Q&A with Pfizer leaders and experts, are designed to provide the investment community with insights into our pipeline and other strategic topics.
Watch this video from Johanna and Megan to hear the key takeaways from our breast cancer-focused Pfizer Plash.
Pfizer is advancing a wide range of investigational therapies in our breast cancer pipeline, with the goal of improving patient outcomes and driving long-term value for shareholders.
For more information on our breast cancer strategy, we invite you to watch the full Pfizer Pflash.
Forward-looking statements included herein and in the linked content, including those related to our anticipated operating and financial performance, our productivity improvement initiatives, our research and development strategy and productivity, our product and pipeline advancements and candidates, and our capital allocation strategy and dividend, speak only as of the original date they were made and are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.
July 2, 2025
Breast cancer is the most common cancer among women globally –and a key focus of Pfizer’s leading oncology portfolio.
In today’s rapidly evolving treatment landscape, breast cancer therapy needs to be tailored to the individual patient. Our Oncology team’s deep understanding of breast cancer biology enables them to prioritize the advancement of innovative potential medicines for certain subtypes of breast cancer, while also working to overcome the biggest challenges in treatment.
In the latest Pfizer Pflash, Francesca DeMartino, Pfizer's Chief Investor Relations Officer, sat down with Johanna Bendell, Chief Development Officer for Pfizer Oncology, and Megan O’Meara, Head of Oncology Early Clinical Development, to discuss our breast cancer strategy, pipeline, and key milestones for promising potential new treatments. Our Pfizer Pflash webcasts, which feature discussions and Q&A with Pfizer leaders and experts, are designed to provide the investment community with insights into our pipeline and other strategic topics.
Pfizer is advancing a wide range of investigational therapies in our breast cancer pipeline, with the goal of improving patient outcomes and driving long-term value for shareholders.
For more information on our breast cancer strategy, we invite you to watch the full Pfizer Pflash.
Forward-looking statements included herein and in the linked content, including those related to our anticipated operating and financial performance, our productivity improvement initiatives, our research and development strategy and productivity, our product and pipeline advancements and candidates, and our capital allocation strategy and dividend, speak only as of the original date they were made and are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.
Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.
Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.